SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

Core Viewpoint - SAB Biotherapeutics, Inc. has appointed David Zaccardelli, Pharm.D. as Chair of the Board and Rita Jain, M.D. as an Independent Director, signaling a strategic enhancement to its leadership team as it advances its clinical-stage biopharmaceutical development for type 1 diabetes and other autoimmune diseases [1][2][3] Leadership Appointments - David Zaccardelli brings over 20 years of biopharmaceutical experience, having successfully led companies from clinical stages to commercialization, including the launch of Ohtuvayre®, a notable biotech product [3][7] - Rita Jain has more than two decades of experience in biopharmaceutical development and clinical strategy, with expertise in autoimmune and inflammatory diseases [5][8] Company Strategy and Vision - The appointments of Zaccardelli and Jain are expected to significantly impact SAB Biotherapeutics' growth trajectory and reinforce confidence in its strategic direction, particularly in advancing SAB-142, a potential game-changing therapy for type 1 diabetes [3][4] - SAB-142 aims to modify the treatment paradigm for type 1 diabetes by delaying onset and potentially preventing disease progression in Stage 3 patients [9] Company Background - SAB Biotherapeutics is focused on developing multi-specific, high-potency human immunoglobulin G (hIgG) to treat immune and autoimmune disorders, utilizing advanced genetic engineering and proprietary technology [9]